BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557-4561. [PMID: 17876013 DOI: 10.1200/jco.2007.12.0949] [Cited by in Crossref: 297] [Cited by in F6Publishing: 114] [Article Influence: 21.2] [Reference Citation Analysis]
Number Citing Articles
1 Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X. Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;1:CD006875. [PMID: 28128439 DOI: 10.1002/14651858.CD006875.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
2 Tonini G, Calvieri A, Vincenzi B, Santini D. First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. Onco Targets Ther 2009;2:73-82. [PMID: 20616896 DOI: 10.2147/ott.s3465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011;13:162-78. [PMID: 21421461 DOI: 10.1007/s12094-011-0636-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
4 Ranieri G, Niccoli Asabella A, Altini C, Fazio V, Caporusso L, Marech I, Vinciarelli G, Macina F, de Ceglia D, Fanelli M, Ammendola M, Rubini G, Gadaleta CD. A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. Onco Targets Ther 2016;9:7527-35. [PMID: 28003766 DOI: 10.2147/OTT.S112670] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
5 Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2013;4:285-298. [PMID: 23997940 DOI: 10.3978/j.issn.2078-6891.2013.028] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
6 Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010;16:974-5. [PMID: 20823880 DOI: 10.1038/nm0910-974] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 7.1] [Reference Citation Analysis]
7 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7:493-507. [PMID: 20551942 DOI: 10.1038/nrclinonc.2010.97] [Cited by in Crossref: 448] [Cited by in F6Publishing: 383] [Article Influence: 40.7] [Reference Citation Analysis]
9 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer 2012;43:562-9. [PMID: 22294255 DOI: 10.1007/s12029-012-9368-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang C, Yang C, Feldman MJ, Wang H, Pang Y, Maggio DM, Zhu D, Nesvick CL, Dmitriev P, Bullova P, Chittiboina P, Brady RO, Pacak K, Zhuang Z. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget 2017;8:56110-25. [PMID: 28915577 DOI: 10.18632/oncotarget.18125] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
12 Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther 2011;12:436-46. [PMID: 21725209 DOI: 10.4161/cbt.12.5.16394] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
13 Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012;7:e38231. [PMID: 22701615 DOI: 10.1371/journal.pone.0038231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
14 Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 2011;47:997-1005. [PMID: 21247755 DOI: 10.1016/j.ejca.2010.12.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
15 McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
16 Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015;6:185-200. [PMID: 25830038 DOI: 10.3978/j.issn.2078-6891.2014.112] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
17 Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S. A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clin Colorectal Cancer 2015;14:154-61. [PMID: 25861837 DOI: 10.1016/j.clcc.2015.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
18 Trindade A, Djokovic D, Gigante J, Mendonça L, Duarte A. Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo. BMC Cancer 2017;17:189. [PMID: 28288569 DOI: 10.1186/s12885-017-3171-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
19 Arora N, Gupta A, Singh PP. Biological agents in gastrointestinal cancers: adverse effects and their management. J Gastrointest Oncol. 2017;8:485-498. [PMID: 28736636 DOI: 10.21037/jgo.2017.01.07] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
20 Jones C, Taylor MA, McWilliams B. The role of cetuximab as first-line treatment of colorectal liver metastases. HPB (Oxford) 2013;15:11-7. [PMID: 23216774 DOI: 10.1111/j.1477-2574.2012.00591.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
21 Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008;99:1729-34. [PMID: 18827815 DOI: 10.1038/sj.bjc.6604681] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
22 Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol 2017;12:775-85. [PMID: 29067643 DOI: 10.1007/s11523-017-0530-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
23 Papadimitriou K, Rolfo C, Dewaele E, Van De Wiel M, Van den Brande J, Altintas S, Huizing M, Specenier P, Peeters M. Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer. Curr Treat Options Oncol 2015;16:18. [PMID: 25813037 DOI: 10.1007/s11864-015-0333-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19-30. [PMID: 22253552 DOI: 10.4137/CMO.S7432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
25 Sullivan KM, Kozuch PS. Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int. 2011;2011:219309. [PMID: 21437184 DOI: 10.4061/2011/219309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
26 Cai J, Han S, Qing R, Liao D, Law B, Boulton ME. In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) 2011;16:803-14. [PMID: 21196204 DOI: 10.2741/3721] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
27 Yoshida K, Yamada Y. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. Transl Lung Cancer Res 2015;4:217-9. [PMID: 26207207 DOI: 10.3978/j.issn.2218-6751.2015.03.04] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
28 Angioni R, Liboni C, Herkenne S, Sánchez-Rodríguez R, Borile G, Marcuzzi E, Calì B, Muraca M, Viola A. CD73+ extracellular vesicles inhibit angiogenesis through adenosine A2B receptor signalling. J Extracell Vesicles 2020;9:1757900. [PMID: 32489531 DOI: 10.1080/20013078.2020.1757900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
29 Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 2015;33:911-20. [PMID: 25990659 DOI: 10.1007/s10637-015-0251-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
31 Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A. New advances in targeted gastric cancer treatment. World J Gastroenterol 2016;22:6776-99. [PMID: 27570417 DOI: 10.3748/wjg.v22.i30.6776] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
32 Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med 2009;15:183-91. [PMID: 19305491 DOI: 10.2119/molmed.2009.00007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
33 Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 2007;10:81-100. [PMID: 17482503 DOI: 10.1016/j.drup.2007.03.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
34 Azizi E, Kittai A, Kozuch P. Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. Chemother Res Pract 2012;2012:198197. [PMID: 23091721 DOI: 10.1155/2012/198197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
35 Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol 2011;38:284-308. [PMID: 21421118 DOI: 10.1053/j.seminoncol.2011.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
36 Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol. 2013;19:8474-8488. [PMID: 24379565 DOI: 10.3748/wjg.v19.i46.8474] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
37 Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012;30:1597-1606. [PMID: 21629990 DOI: 10.1007/s10637-011-9691-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
38 Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010;9:843-56. [PMID: 21031001 DOI: 10.1038/nrd3216] [Cited by in Crossref: 168] [Cited by in F6Publishing: 136] [Article Influence: 15.3] [Reference Citation Analysis]
39 Greening DW, Lee ST, Ji H, Simpson RJ, Rigopoulos A, Murone C, Fang C, Gong S, O'Keefe G, Scott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget 2015;6:38166-80. [PMID: 26517691 DOI: 10.18632/oncotarget.6241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
40 Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med. 2014;3:572-579. [PMID: 24574334 DOI: 10.1002/cam4.208] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
41 Ishima Y, Inoue A, Fang J, Kinoshita R, Ikeda M, Watanabe H, Maeda H, Otagiri M, Maruyama T. Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide. Cancer Sci 2015;106:194-200. [PMID: 25457681 DOI: 10.1111/cas.12577] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
42 Li Y, Chen X, Li W, Ye Y, Du X, Sun S, Liu L, Zhang H. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. Front Oncol 2021;11:684309. [PMID: 34109130 DOI: 10.3389/fonc.2021.684309] [Reference Citation Analysis]
43 Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603. [PMID: 18650835 DOI: 10.1038/nrc2442] [Cited by in Crossref: 1958] [Cited by in F6Publishing: 1727] [Article Influence: 150.6] [Reference Citation Analysis]
44 Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, Taieb J. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 2018;29:835-56. [PMID: 29452346 DOI: 10.1093/annonc/mdy038] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 13.5] [Reference Citation Analysis]
45 Pinto MP, Sotomayor P, Carrasco-Avino G, Corvalan AH, Owen GI. Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. Int J Mol Sci 2016;17:E1489. [PMID: 27608016 DOI: 10.3390/ijms17091489] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
46 Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 2020;9:7. [PMID: 32337094 DOI: 10.1186/s40164-020-00159-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
47 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
48 Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6:CD007047. [PMID: 28654140 DOI: 10.1002/14651858.cd007047] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 2009;1:222-9. [PMID: 20065642 DOI: 10.4161/mabs.1.3.8292] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
50 Demir R, Peros G, Hohenberger W. Definition of the "Drug-Angiogenic-Activity-Index" that allows the quantification of the positive and negative angiogenic active drugs: a study based on the chorioallantoic membrane model. Pathol Oncol Res 2011;17:309-13. [PMID: 21221880 DOI: 10.1007/s12253-010-9318-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
52 Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res 2017;8:591-605. [PMID: 28808589 DOI: 10.1016/j.jare.2017.06.006] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 20.3] [Reference Citation Analysis]
53 Jehn CF, Böning L, Kröning H, Possinger K, Lüftner D. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 2012;106:274-8. [PMID: 22215062 DOI: 10.1038/bjc.2011.554] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
54 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Park SR, Davis M, Doroshow JH, Kummar S. Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol 2013;10:154-68. [PMID: 23358316 DOI: 10.1038/nrclinonc.2012.245] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
56 Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S18-30. [PMID: 20680104 DOI: 10.3747/co.v17is1.615] [Cited by in Crossref: 11] [Cited by in F6Publishing: 35] [Article Influence: 1.1] [Reference Citation Analysis]
57 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
58 Ocean AJ, Polite B, Christos P, Horvath L, Hamilton A, Matulich D, Chen HX, Sparano JA, Kindler HL. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer 2010;9:290-6. [PMID: 21208843 DOI: 10.3816/CCC.2010.n.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
59 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
60 Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 2014;1:540-9. [PMID: 25594061 DOI: 10.18632/oncoscience.73] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
61 Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics 2008;2:223-8. [PMID: 19707356 DOI: 10.2147/btt.s1980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 0.3] [Reference Citation Analysis]
62 Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;6:CD007047. [PMID: 28654140 DOI: 10.1002/14651858.CD007047.pub2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
64 Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310. [PMID: 18471507 DOI: 10.1053/j.gastro.2008.02.098] [Cited by in Crossref: 307] [Cited by in F6Publishing: 240] [Article Influence: 23.6] [Reference Citation Analysis]
65 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
66 Carla C, Daris F, Cecilia B, Francesca B, Francesca C, Paolo F. Angiogenesis in head and neck cancer: a review of the literature. J Oncol 2012;2012:358472. [PMID: 22131994 DOI: 10.1155/2012/358472] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
67 Klupp F, Sass M, Bergmann F, Khajeh E, Ghamarnejad O, Hassenpflug M, Mehrabi A, Kulu Y. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncol Lett 2021;21:448. [PMID: 33868486 DOI: 10.3892/ol.2021.12709] [Reference Citation Analysis]
68 Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, Avola R, Salmeri M, Nicoletti F, Anfuso CD. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Front Pharmacol. 2016;7:519. [PMID: 28111549 DOI: 10.3389/fphar.2016.00519] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
69 Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathol Oncol Res. 2017;23:673-677. [PMID: 28025786 DOI: 10.1007/s12253-016-0166-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
70 Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2017;2:90380. [PMID: 28422758 DOI: 10.1172/jci.insight.90380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
71 Cercek A, Saltz L. Evolving treatment of advanced colorectal cancer. Curr Oncol Rep. 2010;12:153-159. [PMID: 20425074 DOI: 10.1007/s11912-010-0096-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
72 Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009;135:855-66. [PMID: 19363621 DOI: 10.1007/s00432-009-0583-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
73 Patel SB, Gill D, Garrido-Laguna I. Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther 2016;9:75-86. [PMID: 26770060 DOI: 10.2147/OTT.S68558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Bhutiani N, Akinwande O, Martin RC. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. World J Surg. 2016;40:1178-1190. [PMID: 26711640 DOI: 10.1007/s00268-015-3386-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
75 Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 2010;15:73-84. [PMID: 20067946 DOI: 10.1634/theoncologist.2009-0167] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
76 Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer. 2012;15:252-264. [PMID: 22011788 DOI: 10.1007/s10120-011-0102-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
77 Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 2010;15:37-50. [PMID: 20080862 DOI: 10.1634/theoncologist.2009-0117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
78 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
79 Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008;66:6-19. [PMID: 18503606 DOI: 10.1111/j.1365-2125.2008.03187.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
80 Seufferlein T, Ahn J, Krndija D, Lother U, Adler G, von Wichert G. Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal 2009;7:19. [PMID: 19678929 DOI: 10.1186/1478-811X-7-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012;5:113-23. [PMID: 23226067 DOI: 10.2147/PGPM.S24258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 0.1] [Reference Citation Analysis]
82 Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011;105:44-52. [PMID: 21629245 DOI: 10.1038/bjc.2011.182] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
83 Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med 2016;8:115. [PMID: 27793177 DOI: 10.1186/s13073-016-0369-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 7.6] [Reference Citation Analysis]
84 Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 2012;17:513-524. [PMID: 22477726 DOI: 10.1634/theoncologist.2012-0003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
85 Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs. 2009;27:253-261. [PMID: 19002384 DOI: 10.1007/s10637-008-9182-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
86 Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D 2011;11:101-11. [PMID: 21679003 DOI: 10.2165/11590440-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
87 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
88 Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, Unger C, Blum H, Hennig J, Milenkova TP. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res. 2009;1:5. [PMID: 19946413 DOI: 10.1186/2040-2384-1-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
89 Mariotte D, Dupont B, Gervais R, Galais MP, Laroche D, Tranchant A, Comby E, Bouhier-Leporrier K, Reimund JM, Le Mauff B. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 2011;3:396-401. [PMID: 21654207 DOI: 10.4161/mabs.3.4.16293] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
90 Oshima T, Masuda M. Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today 2012;42:313-27. [PMID: 22127535 DOI: 10.1007/s00595-011-0065-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
91 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
92 Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015;6:60-74. [PMID: 25642339 DOI: 10.3978/j.issn.2078-6891.2014.098] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
93 Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, Jackson C, Chatterjee D, Pricolo V, Roth L, Shah N, Cataldo T, Safran H, Hixson D, Quesenberry P. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol 2013;95:74-82. [PMID: 23528430 DOI: 10.1016/j.yexmp.2013.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
94 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
95 Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 2016;37:127-40. [PMID: 26566626 DOI: 10.1007/s13277-015-4408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
96 Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. 2010;2010:132641. [PMID: 20445741 DOI: 10.1155/2010/132641] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
97 Chandrasekhar JL, Cox KM, Erickson LD. B Cell Responses in the Development of Mammalian Meat Allergy. Front Immunol 2020;11:1532. [PMID: 32765532 DOI: 10.3389/fimmu.2020.01532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
99 Marshall JL. Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? J Oncol 2009;2009:937305. [PMID: 20016807 DOI: 10.1155/2009/937305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
100 Loupakis F, Cremolini C, Fontanini G, Stasi I, Salvatore L, Falcone A. Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Ther Adv Med Oncol 2009;1:167-81. [PMID: 21789120 DOI: 10.1177/1758834009348984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
101 Loong HH, Ma BB, Chan AT. Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol 2009;2009:967920. [PMID: 19365583 DOI: 10.1155/2009/967920] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
102 Song X, Long SR, Barber B, Kassed CA, Healey M, Jones C, Zhao Z. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012;7:56-65. [PMID: 22299770 DOI: 10.2174/157488412799218806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
103 Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10:247-57. [PMID: 19201650 DOI: 10.1016/S1470-2045(09)70002-6] [Cited by in Crossref: 206] [Cited by in F6Publishing: 75] [Article Influence: 17.2] [Reference Citation Analysis]
104 De Costa AM, Young MR. Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs 2011;22:674-81. [PMID: 21037467 DOI: 10.1097/CAD.0b013e328340fd18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
105 Kaveh S, Ebrahimi P, Rezapour A, Mozafari M, Sayehmiri K. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. Int J Clin Pharm 2019;41:30-41. [PMID: 30610548 DOI: 10.1007/s11096-018-0754-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2009;2:9. [PMID: 19236713 DOI: 10.1186/1756-8722-2-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
107 Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol. 2010;7:508-519. [PMID: 20700108 DOI: 10.1038/nrclinonc.2010.116] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 7.0] [Reference Citation Analysis]
108 Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 2016;7:9309-21. [PMID: 26824184 DOI: 10.18632/oncotarget.7008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
109 Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 2011;67:465-74. [PMID: 21079958 DOI: 10.1007/s00280-010-1507-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
110 Dienstmann R, De Dosso S, Felip E, Tabernero J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 2012;6:15-26. [PMID: 22189054 DOI: 10.1016/j.molonc.2011.11.009] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 5.5] [Reference Citation Analysis]
111 Fakih M, Wong R. Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17 Suppl 1:S3-17. [PMID: 20680105 DOI: 10.3747/co.v17is1.616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
112 Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12:508-16. [PMID: 20406901 DOI: 10.1093/neuonc/nop063] [Cited by in Crossref: 18] [Cited by in F6Publishing: 73] [Article Influence: 1.6] [Reference Citation Analysis]
113 Cea V, Sala C, Verpelli C. Antiangiogenic therapy for glioma. J Signal Transduct 2012;2012:483040. [PMID: 22830012 DOI: 10.1155/2012/483040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
114 Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 2008;5:16. [PMID: 19116012 DOI: 10.1186/1742-4933-5-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]